Engineering Adenoviral Vectors with Improved GBM Selectivity.

Area of Science:

• Oncolytic virotherapy
• Cancer biology
• Gene therapy

Background:

• Glioblastoma (GBM) is an aggressive brain cancer with poor prognosis.
• Oncolytic adenoviruses offer a potential therapeutic strategy for GBM.
• Human adenovirus 5 (HAdV-C5) use is limited by pre-existing immunity and off-target effects.

Purpose of the Study:

• To investigate alternative adenoviral tropisms for improved GBM targeting.
• To develop strategies for enhancing GBM-specific transgene expression.

Main Methods:

• Adenovirus platform pseudotyped with fiber knob proteins from alternative serotypes.
• Analysis of adenoviral receptor expression (CAR, CD46, DSG2) in GBM and healthy brain tissue.
• Utilized tumor-specific promoters (hTERT, survivin) to drive reporter gene expression.

Main Results:

• Adenoviral pseudotypes effectively transduced GBM cells via CAR, CD46, and DSG2.
• These receptors are also present on healthy brain cells, indicating potential off-target effects.
• Tumor-specific promoters (hTERT, survivin) demonstrated selective reporter gene expression in GBM cell lines.

Conclusions:

• Pseudotyping adenoviruses can enhance GBM cell transduction.
• Combining pseudotyping with tumor-specific promoters offers a strategy to improve GBM therapy specificity.
• This approach may lead to more efficacious and targeted oncolytic virotherapies for glioblastoma.